Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

Francis J. Giles, Gary Guangping Shi, Jorge E. Cortes, Deborah Thomas, Anna R. Keating, Hagop M. Kantarjian, Michael J. Keating, Susan M. O'Brien

Research output: Contribution to journalArticle

3 Scopus citations


Purpose: Amifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy. The combination of fludarabine and cyclophosphamide (FC) is highly active in patients with chronic lymphocytic leukemia (CLL). Infection is a serious toxicity of the FC regimen. Methods: Amifostine was added to the FC regimen in a phase II study of 46 patients with CLL. Patients received FCA (fludarabine 30 mg/m2 i.v. daily for 3 days, cyclophosphamide 300 mg/m2 i.v. daily for 3 days, and amifostine 500 mg i.v. over 15 min daily for 3 days starting 30 min before cyclophosphamide) at intervals of 4-6 weeks for a maximum of six courses. Results: Patients receiving FCA had equivalent rates of sepsis, early death, objective response and survival to those observed in a prior series of 78 patients treated with FC. Amifostine-associated toxicities included nausea, vomiting, and hypotension. Conclusion: The study amifostine regimen did not reduce the toxicity or activity of the FC regimen in patients with CLL.

Original languageEnglish (US)
Pages (from-to)223-228
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Issue number3
StatePublished - Sep 1 2003
Externally publishedYes



  • Amifostine
  • Chronic lymphocytic leukemia
  • Cyclophosphamide
  • Fludarabine
  • Sepsis

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this